Segment Information (Tables)

9 Months Ended

Sep. 30, 2019

Segment Information

Summary of results of operations by segment

			Contract		Corporate		Total
Three Months Ended September 30, 2019	Therapeutics		Research		and Other		Company
Revenue, net	$	—	$	2,943	$	(1,960)	$	983
Cost of revenue (excludes amortization)		—		2,724		(1,898)		826
Research and development		16,245		—		(62)		16,183
Sales and marketing		96		16		—		112
General and administrative		—		956		5,770		6,726
Amortization of definite-lived intangible		—		—		—		—
Loss from operations	$	(16,341)	$	(753)	$	(5,770)	$	(22,864)
Loss from discontinued operations	$	(30,915)	$	—	$	(960)	$	(31,875)
			Contract		Corporate		Total
Three Months Ended September 30, 2018	Therapeutics		Research		and Other		Company
Revenue, net	$	—	$	3,225	$	(2,107)	$	1,118
Cost of revenue		—		2,823		(1,756)		1,067
Research and development		15,189		—		—		15,189
Sales and marketing		49		14		—		63
General and administrative		—		566		5,575		6,141
Loss from operations	$	(15,238)	$	(178)	$	(5,926)	$	(21,342)
Loss from discontinued operations	$	(11,675)	$	—	$	(433)	$	(12,108)
			Contract		Corporate		Total
Nine Months Ended September 30, 2019	Therapeutics		Research		and Other		Company
Revenue, net	$	—	$	11,940	$	(8,808)	$	3,132
Cost of revenue (excludes amortization)		—		11,584		(8,556)		3,028
Research and development		53,585		—		(251)		53,334
Sales and marketing		581		48		—		629
General and administrative		—		2,069		19,073		21,142
Goodwill impairment		18,504		—		—		18,504
Amortization of definite-lived intangible		—		—		—		—
Loss from operations	$	(72,670)	$	(1,761)	$	(19,074)	$	(93,505)
Loss from discontinued operations	$	(45,636)	$	—	$	(2,724)	$	(48,360)
			Contract		Corporate		Total
Nine Months Ended September 30, 2018	Therapeutics		Research		and Other		Company
Revenue, net	$	1,000	$	8,779	$	(5,400)	$	4,379
Cost of revenue		—		7,564		(4,501)		3,063
Research and development		41,482		—		—		41,482
Sales and marketing		55		34		—		89
General and administrative		—		1,557		18,924		20,481
Loss from operations	$	(40,537)	$	(376)	$	(19,823)	$	(60,736)
Loss from discontinued operations	$	(35,166)	$	—	$	(474)	$	(35,640)